1. ALLA AKTIER
  2. NYHETER
  3. AROCELL

AroCell

Nyheter AroCell Nyheter alla bolag

IDL Diagnostics will have a Strategy Update on the 27th of November

IDL Diagnostics AB (publ) invites investors, media and the public to virtually attend a Live Strategy Update on the 27th of November 2025 at 09:00 at Redeye (www.redeye.se).

CEO Anders Hultman and members of the management team will inform about recent progress and key strategic activities and opportunities for 2026 and beyond.

Following the presentation there will be a Q&A session moderated by Redeye analyst Oscar Bergman.

Viewers will have the opportunity to ask questions through the webcast video chat.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@idldiagnostics.com

About IDL Diagnostics

IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.idldiagnostics.com

Attachments

IDL Diagnostics will have a Strategy Update on the 27th of November

Datum 2025-11-12, kl 11:05
Källa MFN
Bifogade filer
IDL Diagnostics will have a Strategy Update on the 27th of November
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!